Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy

Détails

ID Serval
serval:BIB_8F0AB4D335C7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy
Périodique
Journal of Clinical Investigation
Auteur(s)
Rizzardi  G. P., Harari  A., Capiluppi  B., Tambussi  G., Ellefsen  K., Ciuffreda  D., Champagne  P., Bart  P. A., Chave  J. P., Lazzarin  A., Pantaleo  G.
ISSN
0021-9738 (Print)
Statut éditorial
Publié
Date de publication
03/2002
Volume
109
Numéro
5
Pages
681-8
Notes
Clinical Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Mar
Résumé
Primary HIV-1 infection causes extensive immune activation, during which CD4(+) T cell activation supports massive HIV-1 production. We tested the safety and the immune-modulating effects of combining cyclosporin A (CsA) treatment with highly active antiretroviral therapy (HAART) during primary HIV-1 infection. Nine adults with primary HIV-1 infection were treated with CsA along with HAART. At week 8, all patients discontinued CsA but maintained HAART. Viral replication was suppressed to a comparable extent in the CsA + HAART cohort and in 29 control patients whose primary infection was treated with HAART alone. CsA restored normal CD4(+) T cell levels, both in terms of percentage and absolute numbers. The increase in CD4(+) T cells was apparent within a week and persisted throughout the study period. CsA was not detrimental to virus-specific CD8(+) or CD4(+) T cell responses. At week 48, the proportion of IFN-gamma-secreting CD4(+) and CD4(+)CCR7(-) T cells was significantly higher in the CsA + HAART cohort than in the HAART-alone cohort. In conclusion, rapid shutdown of T cell activation in the early phases of primary HIV-1 infection can have long-term beneficial effects and establish a more favorable immunologic set-point. Appropriate, immune-based therapeutic interventions may represent a valuable complement to HAART for treating HIV infection.
Mots-clé
Adjuvants, Immunologic/*administration & dosage/adverse effects Adult *Antiretroviral Therapy, Highly Active/adverse effects CD4 Lymphocyte Count CD4-Positive T-Lymphocytes/drug effects/immunology Cyclosporine/*administration & dosage/adverse effects HIV Infections/*drug therapy/immunology/virology HIV-1/drug effects Humans Middle Aged Prospective Studies Receptors, Chemokine/metabolism Safety T-Lymphocyte Subsets/drug effects/immunology Virus Replication/drug effects
Pubmed
Web of science
Création de la notice
25/01/2008 16:00
Dernière modification de la notice
03/03/2018 19:20
Données d'usage